

# Risk Factors of Cardiovascular Complications Among Patients with Prediabetes in Andijan City and Markhamat District of the Republic of Uzbekistan According to Screening Data

Yusupova Sh. K.<sup>1</sup>, Abdurakhmanova R. Kh.<sup>2</sup>

<sup>1</sup>Associate Professor, Head of the Department of Hospital Therapy and Endocrinology, Doctor of Medical Sciences, Andijan State Medical Institute, Andijan, Uzbekistan

<sup>2</sup>Free Applicant of the Department of Hospital Therapy and Endocrinology, Andijan State Medical Institute, Andijan, Uzbekistan

**Abstract** This study examines the prevalence and risk factors for cardiovascular complications among individuals with prediabetes in Andijan city and Markhamat district of Uzbekistan. A total of 3400 individuals at risk were screened using anthropometric, clinical, biochemical, and instrumental methods. The analysis focused on body mass index, waist circumference, blood pressure, lipid profile, physical activity, and family history of diabetes and cardiovascular diseases. Results showed significant differences in the prevalence of type 2 diabetes mellitus and associated cardiovascular risks between urban and rural populations. Key predictors of cardiovascular complications included high BMI, increased triglyceride levels, chronic heart failure, and genetic predisposition. The findings emphasize the importance of early detection and targeted prevention strategies for high-risk groups.

**Keywords** Risk factors, Type 2 diabetes mellitus, Prediabetes

## 1. Introduction

Type 2 diabetes mellitus (DM 2) is a category of metabolic disorders characterized by hyperglycemia, which occurs when the pancreas stops producing enough insulin or when the body cannot use it. Diabetes causes many complications that are associated with increased morbidity and mortality [1,2]. Type 2 diabetes mellitus was prevalent in 9.3% of the world's population [3]. Mortality rates from type 2 DM decreased from 2000 to 2010, then increased from 2010 to 2016 in developed countries, while mortality rates from type 2 DM increased in low-income countries during both periods [4]. The increase in prevalence and incidence of DM 2 has been attributed to changes in urban habits that are associated with sedentary lifestyles [5].

The last 2-3 decades have witnessed marked lifestyle changes with significant population growth and urbanization, which are major risk factors that have been repeatedly reported.

Pre-diabetes mellitus (pre-DM) is a general term that refers to an intermediate state of abnormal glycemia. It is also known as impaired glucose regulation (IG), which includes 2 groups of individuals: subjects with impaired fasting glucose

(IFG) and subjects with impaired glucose tolerance (IGT). [1]. It is increasing worldwide, and the number of people with pre-DM worldwide is estimated to reach 472 million by 2025, the authors noted in 2015. [2].

Pre-DM has received increasing attention in the literature in recent years as it has become a huge public health burden in general and in several countries where the incidence of Pre-DM has reached 50.1% among adults. This has become a concern about the impact of Pre-DM on macrovascular events, and research is urgently needed to strengthen evidence-based treatment recommendations for patients with pre-DM 2.

A recent systematic review concluded that UWG does not or only slightly increases the risk of cardiovascular disease, whereas a community-based study found that glycohemoglobin levels, not fasting glucose levels, are significantly associated with cardiovascular disease. Another significant study from Korea found that an increased risk of myocardial infarction was only seen with glucose levels characteristic of diabetes. At the same time, other researchers have noted that hyperglycemia within the nondiabetic glucose range is associated with an increased risk of cardiovascular disease [13].

As we all know, cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide, and DM is a risk factor for serious chronic diseases, including CVD [5-7]. However, studies on the presence and accumulation of CVD

risk factors in the NRH stage have been scarce and have not reached a general consensus. [8-12]. In addition, few articles were found in the literature on CVD risk associated with blood glucose. Therefore, the question arose about the association of risk factors for the development of CVDs in prediabetics in the Uzbek population.

All of the above provided the basis for the present study.

**The aim of the study was to** investigate risk factors for cardiovascular complications among prediabetic patients in Andijan city and Markhamat district of the Republic of Uzbekistan according to the screening data.

## 2. Material and Methods of Research

The study was conducted on the basis of Andijan State Medical Institute. A total of 3400 persons of risk groups were examined, of which 1800 were residents of Markhamat district of Andijan region and 1600 residents of Andijan city. The control group consisted of 30 healthy individuals.

Inclusion criteria: individuals over 20 years of age who were overweight, dyslipidemic, or hypertensive.

Exclusion criteria: type 1 diabetes mellitus, other endocrine diseases, metformin use, severe autoimmune diseases, vasculitis, oncology.

According to the design, the study was conducted in two phases.

In Phase 1, according to the study design, cardiovascular risk factors including waist circumference, body mass index (BMI), blood pressure level, lipid profile, presence of diabetes mellitus and metabolic syndrome, and anamnestic information extracted from relevant medical records were analyzed. Patients were questioned using the Findrisk scale.

At the 2nd stage, freshly collected biological material (venous blood) was collected and then promptly delivered to the laboratory for research.

The study methods included general clinical approaches, biochemical testing (measurement of fasting blood glucose levels and two hours after meals, determination of glycated hemoglobin, bilirubin (both direct and indirect), as well as ALT, AST, PTL, coagulogram, C-reactive protein, urea, creatinine and lipid profile), hormonal tests (insulin and C-peptide levels in the blood as needed) and instrumental methods such as ECG, ultrasound of endocrine glands and internal organs, chest X-ray and other tests.

Diabetes mellitus (DM) is diagnosed based on glucose levels 2 hours after a meal, as well as fasting glucose values or self-reported DM at initial screening. Impaired fasting glycemia (IFG) is defined as a fasting glucose level of 5.6 to less than 7.0 mmol/L and a 2-hour glucose level of less than 7.8 mmol/L. Impaired glucose tolerance (IGT) is defined as a 2-hour glucose level between 7.8 and less than 11.1 mmol/L. Both conditions, IFG and IGT, have boundaries corresponding to nondiabetic glucose levels both on an empty stomach and after 2 hours. Glucose dysregulation disorder (GDD) denotes the presence of IUGR or IGT, either alone or in combination.

Hypertension was defined as mean blood pressure (with

systolic pressure  $\geq 140$  mm Hg or diastolic pressure  $\geq 90$  mm Hg) or on the basis of self-reported presence of hypertension at baseline.

Cardiovascular disease (CVD) was defined through self-reported diagnosis or medication use during the visit, and medical records were also reviewed when possible. This category included coronary heart disease and cerebrovascular disease. Coronary heart disease further included angina pectoris, myocardial infarction, coronary angiography abnormalities, cardiac procedures, and death due to or in combination with coronary heart disease.

Cerebrovascular disease covered transient cerebral ischemic attack, stroke, cerebral infarction from any cause, and death associated with these conditions.

Data were expressed as mean  $\pm$  DM 2, n (%) or OR (95% CI), all statistical tests were two-sided, and a P value  $< 0.05$  was considered statistically significant.

## 3. Results of the Study

Table 1 gives the distribution of patients of Markhamat district and Andijan city.

**Table 1.** Distribution of selected patients of Markhamat district and Andijan city with carbohydrate metabolism disorders

groups	Markhamat district n=184		Andijan city n=180	
	abs.	%	abs.	%
IFG	19	10.3	20	11.1
IGT	30	16.3	30	16.6
IFG+IGT	53	28.8	50	27.7
DM 2.	52	28.2	50	27.7
NCMD	30	16.3	30	16.6

Note: IFG - impaired fasting glycemia, IGT - impaired glucose tolerance, DM 2 - type 2 diabetes mellitus, NCMD - no carbohydrate metabolism disorders

It should be noted that the largest number of patients was in the 45-59 age period in the pilot regions.

Table 2 gives anthropometric, biochemical and socio-demographic data of patients with prediabetes and at risk of cardiovascular complications of residents of Markhamat district.

Table 3 shows anthropometric, biochemical and socio-demographic data of patients at risk of developing type 2 diabetes mellitus in Andijan city.

The prevalence of DM2 was higher in the elderly (age  $\geq 40$ ) years compared with the aged (age  $< 40$  years) in almost all included studies, except for the findings of Worku & Yeshaneh study, which contradicted other findings. The overall prevalence of DM2 was about 5.95% for age  $\geq 40$  years and 3.6% for patients whose age was less than 40 years. Similarly, BMI was positively associated with DM2, with a mean overall prevalence of DM2 of about 3.6% for those with BMI  $< 25$  kg/m<sup>2</sup>, while the prevalence of DM2 was about 6.98% for those with BMI  $\geq 25$  kg/m<sup>2</sup>. The mean prevalence of DM2 was higher in illiterates, which is about

8.19%. The association of DM2 and alcohol consumption was that a person who consumed alcohol was more prone to DM2 compared to those who did not. This was similar in smokers. The overall mean prevalence of DM2 was 7.1% among smokers and 4.26% among alcohol drinkers. In addition, blood pressure and circumference of exhaustion were also associated with DM2. Among the included studies, there was a prevalence of about 9.89% of DM2 among people with blood pressure  $\geq 140$  mm Hg, while 5.46% of people with blood pressure  $< 140$  mm Hg.

In this study, there was a significant difference in the cumulative prevalence of type 2 DM among the residents of Markhamat district and Andijan city, which was 7.3% and 8.7%, respectively.

The current study also shows that family history of DM, large waist circumference, and hypertension (blood pressure)  $\geq 140$  mm Hg were more likely to be affected by type 2 DM. This idea reflects that family history, waist circumference and hypertension (blood pressure) were significant risk factors for type 2 DM.

**Table 2.** Anthropometric, biochemical and socio-demographic data of patients with prediabetes and at risk of cardiovascular complications of residents of Markhamat district

indicators	Average performance MARKHAMAT				
	NHIS, n=19	IGT, n=30	IFG+IGT, n=53	DM 2, n=52	Control, n=30
Age	52,3 $\pm$ 14,9	51,4 $\pm$ 13,1	51,6 $\pm$ 13,0	51,3 $\pm$ 14,7	51,4 $\pm$ 13,1
BMI	27,2 $\pm$ 3,8	28,6 $\pm$ 4,2	27,7 $\pm$ 3,2	30,0 $\pm$ 6,8*	26,2 $\pm$ 3,4
OT	104,9 $\pm$ 8,1*	107,7 $\pm$ 8,5*	105,9 $\pm$ 6,7*	109,4 $\pm$ 11,0*	88,9 $\pm$ 6,1
CAD, mm Hg	132,7 $\pm$ 7,9	133,4 $\pm$ 9,6	137,7 $\pm$ 8,3*	143,6 $\pm$ 8,7*	130,7 $\pm$ 8,6
MAP, mm	79,3 $\pm$ 8,7	82,8 $\pm$ 10,6*	84,6 $\pm$ 10,2*	78,9 $\pm$ 11,7	75,5 $\pm$ 6,7
Triglycerides (mmol/L)	1,6 $\pm$ 0,5	2,0 $\pm$ 0,9	1,9 $\pm$ 1,1*	1,4 $\pm$ 0,5	1,4 $\pm$ 0,5
HDL-C (mmol/L)	1,5 $\pm$ 0,4	1,5 $\pm$ 0,4	1,5 $\pm$ 0,4	1,4 $\pm$ 0,2	1,4 $\pm$ 0,3
Smoking (number of years)	5,1 $\pm$ 0,9	3,2 $\pm$ 1,7	3,8 $\pm$ 0,9	7,7 $\pm$ 1,9*	5,0 $\pm$ 0,8
Physical activity	3,1 $\pm$ 1,7	3,2 $\pm$ 1,8	2,8 $\pm$ 1,9*	3,8 $\pm$ 1,7*	2,2 $\pm$ 0,6
Alcohol consumption per week	3,9 $\pm$ 0,9*	4,1 $\pm$ 1,3*	4,0 $\pm$ 1,8*	3,2 $\pm$ 1,8*	1,2 $\pm$ 0,3
MetS (N, %)	14 (73.6)	17 (56.6)	12 (22.6)	4 (7.69)	14 (46.6)
Nasl. Aggravation. On DM 2	3 (15.7) *	5 (16.6) *	8 (15.0) *	12 (23.0) *	-
Nasl. Aggravation. By GCC	2 (10.5) *	3 (10.0) *	6 (11.3) *	10 (19.2) *	-

Note: CAD - systolic BP (mm Hg), DBP - diastolic BP (mm Hg), Nasl. Aggravation. On DM 2 - hereditary aggravation by DM 2, Nasl Aggravation by CVD - hereditary aggravation by cardiovascular diseases, \* - reliability of differences in comparison with control, where  $p < 0.005$ .

**Table 3.** Anthropometric, biochemical and socio-demographic data of patients with prediabetes and at risk of cardiovascular complications of residents of Markhamat district

indicators	Average performance Andijan				
	NHIS n=20	IGT n=30	IFG+ IGT n=50	DM 2 n=50	Control n=30
Age	50.2 $\pm$ 8.4	52.3 $\pm$ 8.1	52.3 $\pm$ 8.0	51.5 $\pm$ 8.7	51,4 $\pm$ 13,1
BMI	28,2 $\pm$ 3,4	29,8 $\pm$ 4,5	28,9 $\pm$ 4,3	31,2 $\pm$ 4,5*	26,2 $\pm$ 3,4
OT	105.7 $\pm$ 7.3*	106.5 $\pm$ 6.2*	107.8 $\pm$ 4.9*	109.8 $\pm$ 6.0*	88,9 $\pm$ 6,1
SBP, mm Hg	134,7 $\pm$ 8,5	140,4 $\pm$ 7,6	139,7 $\pm$ 8,2*	146,6 $\pm$ 8,7*	130,7 $\pm$ 8,6
DBP, mm	84,6 $\pm$ 6,5	83,9 $\pm$ 5,6*	87,8 $\pm$ 6,2*	89,9 $\pm$ 6,5*	75,5 $\pm$ 6,7
Triglycerides (mmol/L)	1,6 $\pm$ 0,8	2,1 $\pm$ 0,8	1,8 $\pm$ 0,2*	1,7 $\pm$ 0,3*	1,4 $\pm$ 0,5
HDL-C (mmol/L)	1,3 $\pm$ 0,6	1,5 $\pm$ 0,8	1,6 $\pm$ 0,4	1,6 $\pm$ 0,5*	1,4 $\pm$ 0,3
Smoking (number of years)	5,4 $\pm$ 0,8	3,5 $\pm$ 0,8	3,6 $\pm$ 0,5	7,9 $\pm$ 0,8*	5,0 $\pm$ 0,8
Physical activity	3,2 $\pm$ 1,5*	3,5 $\pm$ 1,2*	2,9 $\pm$ 1,5	3,9 $\pm$ 1,2*	2,2 $\pm$ 0,6
Alcohol consumption	3,5 $\pm$ 0,5*	4,3 $\pm$ 1,2*	4,1 $\pm$ 1,3*	3,9 $\pm$ 0,6*	1,2 $\pm$ 0,3
MetS (N, %)	14 (73.6)	17 (56.6)	12 (22.6)	4 (7.69)	14 (46.6)
Aggravated DM 2.	3 (15.7)	5 (16.6)	8 (15.0)	12 (23.0)	-
Aggravated CVD.	2 (10.5)	3 (10.0)	6 (11.3)	10 (19.2)	-

Note: SBP - systolic BP (mm Hg), DBP - diastolic BP (mm Hg), Aggravation. On DM 2 - hereditary aggravation by DM 2, Aggravation by CVD - hereditary aggravation by cardiovascular diseases, \* - reliability of differences in comparison with control, where  $p < 0.005$ .

**Table 4.** Correlation of various indices with metabolic syndrome (MS). Results of binary logistic regression analysis

Indicators	$\beta$	Wald	df	P	e $\beta$ (odds ratio)	e $\beta$ range
CHS	1.7	11.7	1	>0,01	5.8	2.1-15.7
Weight (kg)	0.1	5.9	1	0,02	1.1	1,0-1,1
Increase in TG	1.2	4.6	1	0,03	3.3	1.1-9.8
Physical activity	-0,3	4.6	1	0,03	0,7	0,6-1,0
Alcohol consumption	0,02	0.2	1	0,67	1.0	0,9-1,1
Smoking (number of years)	0.01	0.1	1	0,75	1.0	0,9-1,0
SEX	0.1	0,03	1	0,86	1.1	0,3-4,9
AH	2.8	0,5	1	0,48	15.9	0,0- $\infty$
BMI	0,6	0.4	1	0,41	1.8	0,3-11,9
Age (years)	0.01	0,02	1	0,71	1.0	1,0-1,0
IFG	1.3	4.4	1	0,05	3.2	1.3-9.7
IGT	1.4	4.5	1	0,06	3.5	1.1-9.6

Note: CHF - chronic heart failure; TG - triglycerides, AH - arterial hypertension

We confirmed that higher BMI is associated with increased insulin resistance and decreased insulin sensitivity in diagnosed type 2 DM patients. This study shows that higher BMI is the most important factor associated with type 2 DM. The results of our study also showed that physical activity was as effective as leisure time exercise in reducing the risk of type 2 DM.

Thus, people over the age of 40 are twice as likely as children to develop type 2 DM.

Table 4 gives the results of the binary logistic regression analysis.

A binary logistic regression model with MI as the dependent variable showed a positive association with CVD, presence of hereditary aggravation for DM2 and CVD, weight, and physical activity (Table 4). Gender, age, height, number of years of smoking, and reported alcohol consumption were not significantly associated.

Stepwise multiple regression analysis with a number of positive MS criteria (systolic and diastolic blood pressure, fasting glucose level, waist circumference, triglycerides and HDL cholesterol) as dependent variable showed a significant effect of weight, weight, physical activity, BMI and age as independent variables.

In this article, we evaluated the association of various associated risk factors for cardiovascular complications such as sex, age, body mass index, family history, hypertension, education level, alcohol consumption, smoking, cholesterol level and waist circumference with type 2 DM.

## 4. Conclusions

1. In this study, there was a significant difference in the cumulative prevalence of type 2 diabetes mellitus among the residents of Markhamat district and Andijan city, which was 7.3% and 8.7%, respectively.
2. A binary logistic regression model with metabolic syndrome as the dependent variable showed a positive association with chronic heart failure, hereditary aggravation for type 2 diabetes mellitus and

cardiovascular disease, weight, and physical activity. Gender, age, height, number of years of smoking, and reported alcohol consumption were not significantly associated.

## REFERENCES

- [1] American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2013 Jan; 36 Suppl 1 (Suppl 1): S67-74. doi: 10.2337/dc13-S067.
- [2] Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. // *Diabetes Care*. 2004 May; 27(5): 1047-53. doi: 10.2337/diacare.27.5.1047.
- [3] Bullard KM, Saydah SH, Imperatore G, Cowie CC, Gregg EW, Geiss LS, Cheng YJ, Rolka DB, Williams DE, Caspersen CJ. Secular changes in U.S. Prediabetes prevalence defined by hemoglobin A1c and fasting plasma glucose: National Health and Nutrition Examination Surveys, 1999-2010. // *Diabetes Care*. 2013 Aug; 36(8): 2286-93. doi: 10.2337/dc12-2563.
- [4] Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G; 2010 China Noncommunicable Disease Surveillance Group. Prevalence and control of diabetes in Chinese adults. // *JAMA*. 2013 Sep 4; 310(9): 948-59. doi: 10.1001/jama.2013.168118.
- [5] Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. // *BMJ*. 2006 Jan 14; 332(7533): 73-8. doi: 10.1136/bmj.38678.389583.7C.
- [6] Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, Folsom AR, Chambless LE; Atherosclerosis Risk in Communities Investigators. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. // *Diabetes Care*. 2005 Aug; 28(8): 2013-8. doi: 10.2337/diacare.28.8.2013.

- [7] Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. // *Diabetes Care*. 1992 Jul; 15(7): 815-9. doi: 10.2337/diacare.15.7.815.
- [8] Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. // *J Am Coll Cardiol*. 2010 Mar 30; 55(13): 1310-7. doi: 10.1016/j.jacc.2009.10.060.
- [9] Liu J, Grundy SM, Wang W, Smith SC Jr, Vega GL, Wu Z, Zeng Z, Wang W, Zhao D. Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome. // *Am Heart J*. 2007 Apr; 153(4): 552-8. doi: 10.1016/j.ahj.2007.01.003.
- [10] Magalhães ME, Cavalcanti BA, Cavalcanti S. Could pre-diabetes be considered a clinical condition? Opinions from an endocrinologist and a cardiologist. *Diabetol Metab Syndr*. 2010 Jan 15; 2: 2. doi: 10.1186/1758-5996-2-2. PMID: 20205782.
- [11] Madssen E, Vatten L, Nilsen TI, Midthjell K, Wiseth R, Dale AC. Abnormal glucose regulation and gender-specific risk of fatal coronary artery disease in the HUNT 1 study. // *Scand Cardiovasc J*. 2012 Aug; 46(4): 219-25. doi: 10.3109/14017431.2012.664646.
- [12] Yang Z, Xing X, Xiao J, Lu J, Weng J, Jia W, Ji L, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, Yang W; China National Diabetes and Metabolic Disorders Study Group. Prevalence of cardiovascular disease and risk factors in the Chinese population with impaired glucose regulation: the 2007-2008 China national diabetes and metabolic disorders study. // *Exp Clin Endocrinol Diabetes*. 2013 Jun; 121(6): 372-4. doi: 10.1055/s-0033-1341520.
- [13] Qiu M, Shen W, Song X, Ju L, Tong W, Wang H, Zheng S, Jin Y, Wu Y, Wang W, Tian J. Effects of prediabetes mellitus alone or plus hypertension on subsequent occurrence of cardiovascular disease and diabetes mellitus: a longitudinal study. // *Hypertension*. 2015 Mar; 65(3): 525-30. doi: 10.1161/HYPERTENSIONAHA.114.04632.